Jon. you, Thank
me RAYALDEE. Turning with to start pharmaceutical our business now let
in months Fresenius. Europe As with and Europe by RAYALDEE European This previously Approvals all the we the This announced of expected submitted granted non-dialysis next application application vitamin last for D approval was in Marketing it one for second was for pending RAYALDEE like others in for Authorization submitted SHPT disease adult Vifor covering Switzerland of patients review. in are request half and kidney another have insufficiency. currently treatment year. for chronic applications accepted
compared the perspective and of XXXX. reported in quarter RAYALDEE follows. the QX for QX IQVIA numbers XX% performance RAYALDEE to commercial as XXXX a compared to increased QX prescriptions by From breakdown as Total XX.X%
XX.X% on total a increased approximately there New of QX Since patient in patients QX. been have versus starts XX,XXX RAYALDEE. launch
also who number prescribe providers RAYALDEE. increased the of healthcare We
patients XXX were We the have with ended of during over QX of which commercially-insured prior prescribers QX quarter. other or having access authorization without restrictions. of As XX% X,XXX written RAYALDEE, new second prescribers
We needed newly professionals. the of and representatives have added are drive expansion frequency XXXX. completed beginning to of the to are the to traction markedly The remainder field to expected our reach XX increased for and provide use latest sales sales RAYALDEE additional in force gain
see sales as continued force. well-trained growth result a larger, of to expect We accelerated the and
on development medical progressing large need portfolio, remain clinical in unmet several Regarding programs, our significant focused markets. addressing with we indications diversified
continues with who X higher renal Phase the and in of we forward in global Tobacco. to Japan patients stage X study a with clinic. Fresenius and are shared September vitamin Vifor require trial insufficiency RAYALDEE in regular D with work this strength initiated CKD Our Last the Costs move being dialysis. a
XX of placebo a be studied the to identify randomized, RAYALDEE in the The cohort. first either or fashion treated cohort to open-label approximately patients be will for appropriate in XX with dosing weeks second
is initial a number XXXX. first of limited Enrollment on originally The QX data had well in expected for planned. patients slower cohort now is readout progressing but we this than
RAYALDEE of QX used Enrollment open-label that include therapies. patient first top-line extended-release completed data demonstrate for XXXX. in in superior is to and X calcifediol studies ongoing an RAYALDEE upcoming anticipated quarter be expected Phase to is and the XX to ongoing study XXXX clinical designed competitive Other commonly are
A with by approved was later FDA patients, a requirement The study with X Phase year. the FDA this in during marketing will this quarter. study for start final post RAYALDEE pediatric protocol second
growth to our human or hGH-CTP. hormone long-acting Somatrogon Turning product,
for worldwide August our This pivotal children was We of hormone Pfizer at with daily As year deficient top-line announcing a partnered know, commercialization. anticipate for months end enrollment complete of you in year. single growth and compares Somatrogon of is the of last data non-inferiority Genotropin and injections end. Somatrogon weekly study injection concluding month this with trial XX before
of XX% as eligible over extension the study into note, with were year therapy the the a sole continuing second treatment. Of Somatrogon patients enter are of to open-label
would rare We at possible our disease additional technologies, CTP, opportunity. forward in to lead plan Somatrogon are and bring is with used candidates significant offer also continuing We each candidates long-acting existing as the significant platform benefit. product therapies our by to efforts PEGylation which where to reverse representing rapidly identify three market a pipeline as least utilizing patient advance for compound new endocrinology
you progress. will We apprised our of keep
to continue our programs. our we commercial across stage milestones stated both make development against Overall, progress and
as provider to We portfolio network selection see growth we proposed every the with for its local including significant Novitas preferred We’ve are and products preferred status the this opportunities will to provider available advanced to our seeing from diversified SOMOS determination multiple laboratory issued and committed test RAYALDEE. of XKscore for making for patient its diagnostics continue across UnitedHealthcare. that use. and a coverage quarter-to-quarter remain benefit BioReference
expecting end. stated for for FDA year approval. a And clinical continues timeline from regulatory line we’re Somatrogon our We before data top our and initiated pathway perspective program XKscore on a
genomic XXXX challenges me for $XXX.X testing three overview, million on $XXX.X detail of let testing. million ended from Revenue period. June XXXX rates a quarter to pre-authorization laboratory within turn of net our were to from that XX, $XXX.X million the XXXX as payer performance. compared the Net specifically revenues PAMA impact period. the the requirements A With services denial decline both were clinical in for environment, compared and XXXX well as reflect our months for the the revenue on decreases second quarter to more the compounding million services $XXX.X financial our for along rate with enhanced the second
genomics testing our to programs operations. laboratory We billing improve line and both on the clinical have implemented of
of some have We are working burden the testing. payers physicians to with to ordering lessen pre-authorizations for
Our are expected and of payers the preferred further discussions these to with payer discussions. ongoing status laboratory help
Medicare In Until received. XKscore addition quarter full not this will final non-coverage we of reimbursement policy draft claims adjudicate to finalization Medicare becomes from the Medicare is the we Upon for beneficiaries. the coverage the the with where work was a not first period. revenue XKscore coverage record policy will from for
product $X.X RAYALDEE June million XXXX period million was period. $X.X for million consistent Revenue XX, compared comparable from the the of $XX.X Revenue sales with ended comparable the with months from during three quarter XXXX to for XXXX. the
result by covered a of Part and of entering D our coverage offset for patients in significantly We Unit increased net discounting donut see as Medicare a by co-pay program. utilization our large decrease growth a RAYALDEE number price and hole. Medicare of patients the utilization card D increased Part our by of was gap
Moving million the the for comparable to to second in period quarter R&D $XX.X we invest and our continue million compared XXXX incurred of programs costs to XXXX. we for where $XX.X of expenses,
of Offsetting $X expense cost by R&D the million was quarter. RAYALDEE our partners during approximately reimbursed
hGH-CTP was of mentioned R&D with its growth our trials our the spend trial. Phase product X biggest as attributable which Our is pivotal pediatric to nearing end hormone
Japanese decrease to the our team partially cost partially second service improve in declining to the $XX our overall, the a by and saw of line rates. our And approximately quarter compared continue we business million within offset of to make We reimbursement of by structure. within laboratory in continue improvements that offset XXXX. structure business, cost revenue -- cost SG&A
Japanese progress. business for has The positions make efficiencies established growth foundation within initiatives us to team operating growth our of as our improved the continue profitable laboratory
our the several were expenses, XXXX sales comparable impacting RAYALDEE overall, There against SG&A loss consistent within as efforts. XXXX. saw we of were period, factors the with net period increased investment other
we $XX.X for the XXXX expense During our resulted million million expense investment compared compared $X.X contingent XXXX, of XXXX period. reversal increase period, the in of the of recorded consideration and a mark-to-market an securities a other of reversal million $XX.X of for to to expense
$X.XX net Overall, per of for of million the $X.X quarter share, loss second the our million net XXXX of compared to $XX.X a $X.XX period during XXXX. increased to loss or or comparable
reimbursement expect to Looking is between after determination revenues obtain This the reflecting third of concludes. the principally XKscore will not the $XXX on a varying to range quarter XXXX, $XXX from services This a million be we we forward of with million. volume continuing assumes and until quarter decrease anticipated pressures, coverage the year-over-year result third expectations.
of announcement expanded expected Medicare half for As the XKscore the as reason into recent -- we announcements mentioned, to our XXXX. provide finalization [TIPA] tailwind status as our Jon SOMOS and as optimism plans decision the well of various entered a laboratory are provide with with we preferred second health head as for our with XXXX and Humana, access coverage
product the revenues, of units, from $X.XX we the quarter. the between million. quarter behind to hole come to grow revenues million, continue from and transfer Medicare million, expected be RAYALDEE donut impact the to unit $XX growth in as associated mix expected $XX continues $XX including in third RAYALDEE $XX million however, and grows the million between the during revenue $X.XX Turning and lags to the is patient third of of million and to property intellectual revenues between expect while
$XX of million $XXX expect our third we includes be Looking between Based loss the expenses on research of and non-cash expenses between we $XX $XX including be development for which depreciation of $XXX at $XX to and operating million and million. and to million anticipate ranges $XX anticipated these million, expense to and quarter, costs XXXX amortization. during quarter third million, million
in will position at and continue we to our cash throughout invest million programs Our mentioned. XXXX R&D as XXth $XXX was previously June
top XXXX. allocation continue will we a as remain capital priority throughout However,
guidance cash we million third of million quarter. during the to utilizing the $XX Given anticipate approximately $XX
commercial performance for second both continued contributions investments which cash the both improved and our during in R&D. of financial for and and of expectations year have diagnostics critical the within We half RAYALDEE our organizations remain
that, Operator? With questions. open to for the call up I’d like
